HIV Prevention Clinical Trial
This study has three specific aims:
1. To conduct a 2-arm randomized controlled trial comparing IMARA to a family-based health
program (FUELTM). The investigators will:
a. Randomly assign 300 14-18 year-old AA or black girls and their primary female
caregivers to IMARA (N=150) or FUELTM (N=150). Women and girls will be recruited four
ways: 1) from mental health clinics using clinic liaisons, 2) flyers will be posted in
clinic recruitment sites and other agencies instructing interested families to call our
recruiter, 3) IMARA participants will hand flyers to interested women and girls they
know, and 4) COIP field station staff will pass out flyers and recruit interested women
and girls at the field stations and in the community. Investigators will examine the
effects of IMARA on women and girls' sexual behavior at 6- and 12-months.
2. To evaluate the impact of IMARA on theoretical mediators posited by the Theory of Gender
and Power and the Social-Personal framework associated with AA women and girls' risky
sex. Investigators will:
1. Assess changes in women and girls' Individual Attributes (HIV/AIDS knowledge,
attitudes, and beliefs, mental health/emotion regulation, ethnic identity); Peer
and Partner Processes (partner characteristics, relationship power dynamics, peer
influences, partner communication); and Family Context (mother-daughter
relationship and communication, parental monitoring) at baseline and follow-ups.
2. Evaluate mediation and moderation of theoretical mechanisms on women and girls'
sexual behavior.
3. To assess the impact of IMARA compared to FUELTM on sexually transmitted infections
(STIs). Investigators will:
1. Test women and girls' urine for three common STIs at baseline and 12-month follow
up.
2. Explore linkages between biological outcomes and targeted mediators and moderators
of change.
Disproportionate rates of mental illness and HIV/STIs among African Americans (AA) reflect
significant health disparities. AAs account for more HIV/AIDS cases, people living with
HIV/AIDS, and HIV-related deaths than any other racial group in the US. In 2004, HIV was the
3rd leading cause of death among Black women, and in 2006, AA women accounted for 66% of new
AIDS cases among women. AA youth ages 13 - 19 comprise approximately 16% of US teens but 69%
of new AIDS cases. Most infections among AA women and girls occur through sexual activity,
and AA girls report more risky sex, less condom use, and lower perceived HIV risk than AA
boys. Racial disparities also exist for AAs in rates of gonorrhea, chlamydia, and syphilis.
Among 15 - 19 year old AA girls, gonorrhea rates are higher than any other race/age/gender
group, and almost half of AA women have an STI. Important linkages exist between HIV/STIs and
mental health; Mental illness is linked to HIV through greater risk taking, poor health
promotion, and reduced effects of behavioral interventions for teens and adults.
HIV-risk factors extend beyond individual women or girls, yet few family-based,
gender-specific, Afrocentric programs simultaneously address AA women, AA girls, mental
health, and the mother-daughter dyad, thereby missing a critical opportunity to address HIV
in a broader social context. Interventions that are sensitive to gender and culture focus on
women (SISTA) or girls (SiHLE) and lack a mental health and family component. Family-based
HIV prevention programs rarely address gender and culture or the adult family member's HIV
risks (Project STYLE). Simultaneously targeting multiple levels in an integrated program --
the mother-daughter dyad, women, and girls -- capitalizes on the reciprocal impact of mothers
and daughters, and facilitates mutual reinforcement of prevention attitudes and behavior,
thereby reducing intervention decay and sustaining positive outcomes over time.
IMARA (Informed, Motivated, Aware, and Responsible about AIDS) blends gender and ethnic
components of SISTA and SiHLE (gender roles, ethnic pride, relationship power) with family
and mental health components from Project STYLE (affect management, parental monitoring,
adolescent development, parent-child communication) to create a culturally relevant,
multi-level, integrated, family-based, HIV and mental health prevention program that
simultaneously targets AA women and their daughters. Based on the Theory of Gender and Power,
the Social-Personal model of HIV-risk, and findings from the investigator's research, IMARA
emphasizes the interplay of family, peer, partner, and individual mechanisms as mediators of
sexual risk taking for women and girls. Pilot testing (N=22 dyads) revealed strong
feasibility, acceptability, and tolerability: >95% consent/assent rates, 96% retention at
2-month follow-up, and very positive feedback. Promising outcome data for mothers and
daughters in targeted mediators (e.g., positive attitudes about HIV/AIDS, greater intentions
to use condoms, increased parental monitoring, more open mother-daughter communication, more
relationship power) and sexual risk outcomes (e.g., increased condom use, fewer partners)
justify a randomized controlled trial.
This study has three specific aims:
1. To conduct a 2-arm randomized controlled trial comparing IMARA to a family-based health
program (FUELTM). Investigators will:
a. Randomly assign 300 14-18 year-old AA or black girls and their primary female
caregivers to IMARA (N=150) or FUELTM (N=150). Women and girls will be recruited four
ways: 1) from mental health clinics using clinic liaisons, 2) flyers will be posted in
clinic recruitment sites and other agencies instructing interested families to call the
study recruiter, 3) IMARA participants will hand flyers to interested women and girls
they know, and 4) COIP field station staff will pass out flyers and recruit interested
women and girls at the field stations and in the community. Investigators will examine
the effects of IMARA on women and girls' sexual behavior at 6- and 12-months.
2. To evaluate the impact of IMARA on theoretical mediators posited by the Theory of Gender
and Power and the Social-Personal framework associated with AA women and girls' risky
sex. Investigators will:
1. Assess changes in women and girls' Individual Attributes (HIV/AIDS knowledge,
attitudes, and beliefs, mental health/emotion regulation, ethnic identity); Peer
and Partner Processes (partner characteristics, relationship power dynamics, peer
influences, partner communication); and Family Context (mother-daughter
relationship and communication, parental monitoring) at baseline and follow-ups.
2. Evaluate mediation and moderation of theoretical mechanisms on women and girls'
sexual behavior.
3. To assess the impact of IMARA compared to FUELTM on sexually transmitted infections
(STIs). Investigators will:
1. Test women and girls' urine for three common STIs at baseline and 12-month follow
up.
2. Explore linkages between biological outcomes and targeted mediators and moderators
of change.
Hypotheses
IMARA participants will report less risky sex (fewer partners, more consistent condom use,
and later sexual debut among non-sexually active girls) at 6- and 12-months and have fewer
incident STI infections at 12-months; and (b) IMARA participants will report positive changes
in theoretical mediators: individual attributes (more positive condom attitudes,
self-efficacy, ethnic pride), peer/partner influences (more relationship power, partner
communication, and awareness of partner influences on sexual decision making), mental health
(improved emotion regulation and understanding of the links between mental illness and risky
sex), mother-daughter communication (more open and comfortable), and mother-daughter
relationships (more parental monitoring and warmth, less parental permissiveness).
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03411577 -
Development and Testing of a Jamaican Mother-daughter HIV Risk-reduction Program
|
N/A | |
Active, not recruiting |
NCT03112369 -
Preventing HIV Among Native Americans Through the Treatment PTSD & Substance Use
|
N/A | |
Not yet recruiting |
NCT03642314 -
HIV Self-testing in Implementation PrEP Study
|
N/A | |
Completed |
NCT01810315 -
Influence of Reproductive Cycle and Menopause on HIV-1 Infection and TFV Gel Activity
|
Phase 1 | |
Completed |
NCT00984971 -
Rectal Microbicide Safety and Acceptability Trial of Topically Applied Tenofovir Compared With Oral Tablet
|
Phase 1 | |
Completed |
NCT00142935 -
Effectiveness of Opiate Replacement Therapy Administered Prior to Release From a Correctional Facility - 1
|
N/A | |
Active, not recruiting |
NCT03255915 -
PrEP-Pod-IVR (TDF-FTC/Placebo IVR 28 Day Crossover Study)
|
Early Phase 1 | |
Completed |
NCT05037513 -
Integrated PrEP Interventions for People Who Inject Drugs in Rural Kentucky
|
N/A | |
Recruiting |
NCT05087680 -
An Acceptance Based PrEP Intervention to Engage Young Black MSM in the South
|
N/A | |
Recruiting |
NCT05804461 -
Optimizing Pre-Exposure Prophylaxis (PrEP) Among Latino Men Who Have Sex With Men (MSM) in Puerto Rico
|
N/A | |
Completed |
NCT03148171 -
Project WERK (Wellness Encouragement Respect Kinship)
|
N/A | |
Completed |
NCT04791007 -
OB-002H Gel Administered Vaginally and Rectally in HIV-1 Seronegative Adults
|
Early Phase 1 | |
Recruiting |
NCT05412433 -
Clinic-based HIV Identification and Prevention Project Using Electronic Resources
|
N/A | |
Active, not recruiting |
NCT03977181 -
The Community PrEP Study to Assess the Acceptance of PrEP Delivered Through CBCT Platforms
|
N/A | |
Recruiting |
NCT05165745 -
Stick2PrEP Cisgender Women and Trans Individuals
|
N/A | |
Completed |
NCT03719053 -
Single Dose Truvada Study
|
Phase 1 | |
Recruiting |
NCT03856580 -
Long-acting Biomedical HIV Prevention in Transgender Women
|
N/A | |
Completed |
NCT02750540 -
Optimization of a Tenofovir Enema for HIV Prevention
|
Phase 1 | |
Completed |
NCT01386294 -
Safety and Effectiveness of Tenofovir Gel in the Prevention of Human Immunodeficiency Virus (HIV-1) Infection in Women and the Effects of Tenofovir Gel on the Incidence of Herpes Simplex Virus (HSV-2) Infection
|
Phase 3 | |
Completed |
NCT00993811 -
The Shang Ring: A Novel Male Circumcision Device for HIV Prevention
|
Phase 1 |